All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Solifenacin Is Effective and Well Tolerated in Patients With Neurogenic Detrusor Overactivity: Results From the Double-Blind, Randomized, Active- and Placebo-Controlled SONIC Urodynamic Study

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F17%3A00124601" target="_blank" >RIV/00216224:14110/17:00124601 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216208:11110/17:10362055 RIV/00216208:11120/17:43915897 RIV/00064190:_____/17:N0000069

  • Result on the web

    <a href="https://onlinelibrary.wiley.com/doi/10.1002/nau.22945" target="_blank" >https://onlinelibrary.wiley.com/doi/10.1002/nau.22945</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1002/nau.22945" target="_blank" >10.1002/nau.22945</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Solifenacin Is Effective and Well Tolerated in Patients With Neurogenic Detrusor Overactivity: Results From the Double-Blind, Randomized, Active- and Placebo-Controlled SONIC Urodynamic Study

  • Original language description

    Aims: To investigate the effect on urodynamics of 4 weeks treatment with solifenacin succinate in patients with neurogenic detrusor overactivity ( NDO) due to multiple sclerosis ( MS) or spinal cord injury ( SCI). Methods: SONIC was a prospective, multicenter, double-blind, phase 3b/4 study investigating the efficacy and safety of solifenacin 10mg in patients with NDO due to MS or SCI. Patients ( n = 189) were randomized to placebo or active treatment ( solifenacin 5 mg, 10mg or oxybutynin hydrochloride 15 mg) for 4 weeks, after a 2-week, single-blind, placebo run-in period. The primary endpoint was change in maximum cystometric capacity ( MCC) from baseline to end of treatment. The primary analysis compared solifenacin 10mg versus placebo; all other comparisons were considered secondary. Secondary endpoints included changes in urodynamic parameters, patient-reported outcomes, and safety assessments. Results: In the primary analysis, solifenacin 10mg significantly improved mean change from baseline MCC versus placebo ( P&lt;0.001) and was associated with improvements in bladder volume at first contraction and at first leak as well as detrusor pressure at first leak. Similar results were obtained for oxybutynin versus placebo. Patient perception of bladder condition significantly improved with solifenacin 10mg versus placebo ( P = 0.041). There was a clear improvement in quality of life ( QoL) in the solifenacin arms versus placebo. The overall incidence of adverse events was low. Conclusions: In patients with NDO due to MS and SCI, 4 weeks of treatment with solifenacin 10mg improved urodynamic variables and QoL versus placebo and was well tolerated. (C) 2015 Wiley Periodicals, Inc.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30217 - Urology and nephrology

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2017

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    NEUROUROLOGY AND URODYNAMICS

  • ISSN

    0733-2467

  • e-ISSN

    1520-6777

  • Volume of the periodical

    36

  • Issue of the periodical within the volume

    2

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    8

  • Pages from-to

    414-421

  • UT code for WoS article

    000394667800032

  • EID of the result in the Scopus database

    2-s2.0-84952837655